DR30206

PreclinicalSmall molecule

ZZhejiang Doer Biologics Co., Ltd.

DR30206 is one of 53 small molecule programs targeting Intestinal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Gastrointestinal CancerRecruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Gastrointestinal CancerPreclinical

Recruiting

Competition

Competitive Landscape

94 competitors in Intestinal Cancer

#DrugCompanyPhaseTrials

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Keytruda

Merck & Co.

Phase 2

3 3

Tukysa

Pfizer

Phase 2

1 4

Fudr

Pfizer

Phase 2

1 5

Pemazyre

Incyte

Phase 2

1 6

Beyfortus

BeiGene

Phase 2

1 7

Trodelvy

Gilead

Phase 2

1 8

Stivarga

Bayer

Phase 2

1 9

Oxaliplatin-Based Chemotherapy

Amgen

Phase 3

1 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT06132828

Q2 2027

PreclinicalRecruiting

Gastrointestinal Cancer

NCT07056777

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors

Recruiting·ZZhejiang Doer Biologics Co., Ltd.·Phase 1·NCT06132828·216 enrolled

Gastrointestinal Cancer1 trial

A Phase Ib/IIa Clinical Trial Evaluating the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Tumors

Recruiting·ZZhejiang Doer Biologics Co., Ltd.·Preclinical·NCT07056777·186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DR30206. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DR30206 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DR30206. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Doer Biologics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhejiang Doer Biologics Co., Ltd.

DR30206

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

Gastrointestinal Cancer1 trial

References

Drug Info

Quick Facts

Related News